

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 March 2022 (31.03.2022)



(10) International Publication Number
WO 2022/067082 A1

(51) International Patent Classification:

A61K 31/41 (2006.01) C07D 257/04 (2006.01)
A61K 31/4192 (2006.01) C07D 257/10 (2006.01)
A61K 31/495 (2006.01) C07D 403/14 (2006.01)

(21) International Application Number:

PCT/US2021/052025

(22) International Filing Date:

24 September 2021 (24.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/084,217 28 September 2020 (28.09.2020) US

(71) Applicant: **CARDURION PHARMACEUTICALS, LLC** [US/US]; 1 Lincoln Street, 30th Floor, Boston, Massachusetts 02111 (US).

(72) Inventors: **MATSUNAGA, Nobuyuki**; c/o Cardurion Pharmaceuticals K.K., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555 (JP). **SHIRAI, Junya**; c/o Cardurion Pharmaceuticals K.K., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555 (JP). **OKAWA, Tomohiro**; c/o Cardurion Pharmaceuticals K.K., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555 (JP). **MIYAMOTO, Yasufumi**; c/o Cardurion Pharmaceuticals K.K., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555 (JP). **SHIOKAWA, Zenyu**; c/o Cardurion Pharmaceuticals K.K., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555 (JP). **NAKAHATA, Takashi**; c/o Cardurion Pharmaceuticals K.K., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555 (JP). **SHIBUYA, Akito**; c/o Cardurion Pharmaceuticals K.K., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555 (JP). **KAWADA, Akira**; c/o Cardurion Pharmaceuticals K.K., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555 (JP). **MACCOSS, Malcolm**; 2556 Seabrook Island Road, Seabrook Island, South Carolina 29455 (US).

(74) Agent: **PINO, Mark** et al.; Mintz Levin Cohn Ferris Glovsky & Popeo, P.C., One Financial Center, Boston, Massachusetts 02111 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS



(I)

(57) Abstract: The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I); wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.

WO 2022/067082 A1